Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials

This publication has 18 references indexed in Scilit:

• Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  The Lancet, 2018
• Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)
  Diabetes, 2018
• Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in E urope and the USA
  Diabetes, Obesity and Metabolism, 2017
• Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
  Cell Death Discovery, 2016
• Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
  Diabetes, Obesity and Metabolism, 2015
• Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
  Diabetes, 2014
• The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
  Diabetes Care, 2014
• Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
  The Lancet, 2014
• The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
  Diabetes Care, 2013
• Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
  Diabetes, Obesity and Metabolism, 2012